European Medicines Agency recommends first-in-class medicine for treatment of Duchenne muscular dystrophy

View source ↗

Summary

EMA recommends a first-in-class medicine for Duchenne muscular dystrophy, signaling potential approval for a novel mechanism in this indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy